Ultragenyx Pharmaceutical (RARE) News Today $38.69 -0.67 (-1.70%) Closing price 04:00 PM EasternExtended Trading$38.70 +0.02 (+0.04%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by BrokeragesUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and thirteen have given a buy ratingMarch 25 at 4:55 AM | marketbeat.comEmerald Advisers LLC Sells 51,470 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Emerald Advisers LLC cut its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 518,328 shares of the biopharmaceutical comMarch 24 at 7:08 AM | marketbeat.com16,810 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Purchased by Simplify Asset Management Inc.Simplify Asset Management Inc. purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 16,810 shares of the biopharmaceutical company's stock, valued at approxMarch 24 at 6:18 AM | marketbeat.comMagnetar Financial LLC Invests $285,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Magnetar Financial LLC acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 6,779 shares of the biopharmaceutical companyMarch 24 at 4:23 AM | marketbeat.comAXQ Capital LP Takes $971,000 Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)AXQ Capital LP purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 23,077 shares of the biopharmaceutical company's stock, valued at apMarch 23 at 7:03 AM | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Reduces Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Connor Clark & Lunn Investment Management Ltd. lowered its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 64.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional invesMarch 21, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) is Privium Fund Management B.V.'s 10th Largest PositionPrivium Fund Management B.V. boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 6.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 258,380 shares of the biopharmaceutical comMarch 20, 2025 | marketbeat.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 19, 2025 | globenewswire.comPiper Sandler Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $115.00March 19, 2025 | americanbankingnews.comDemystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst ReviewsMarch 18, 2025 | benzinga.comUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $115.00 by Analysts at Piper SandlerPiper Sandler reduced their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday.March 18, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 613,633 shares of the bMarch 18, 2025 | marketbeat.comUltragenyx price target lowered to $115 from $140 at Piper SandlerMarch 17, 2025 | markets.businessinsider.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Great Lakes Advisors LLCGreat Lakes Advisors LLC cut its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 4.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 191,129 shares of the biopharmaceutical companMarch 14, 2025 | marketbeat.comInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Sells 1,785 Shares of StockUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 1,785 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the sale, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. The trade was a 1.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 11, 2025 | marketbeat.comBank of New York Mellon Corp Sells 33,112 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Bank of New York Mellon Corp decreased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 4.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 738,973 shares of the biopharmaceutical company's stocMarch 9, 2025 | marketbeat.comUltragenyx Pharmaceutical (RARE) Gets a Buy from J.P. MorganMarch 8, 2025 | markets.businessinsider.comUltragenyx assumed with an Overweight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comCandriam S.C.A. Sells 38,835 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Candriam S.C.A. cut its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 5.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 674,257 shares of the biopharmaceutical company's stock after selliMarch 7, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Theodore Alan Huizenga Sells 967 SharesUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CAO Theodore Alan Huizenga sold 967 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the sale, the chief accounting officer now owns 50,265 shares of the company's stock, valued at approximately $2,116,156.50. This represents a 1.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.March 5, 2025 | marketbeat.comInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Sells 6,028 Shares of StockUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) EVP Thomas Richard Kassberg sold 6,028 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $253,778.80. Following the transaction, the executive vice president now owns 265,238 shares in the company, valued at approximately $11,166,519.80. This trade represents a 2.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.March 5, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Insider Sells $607,881.90 in StockUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) insider John Richard Pinion sold 14,439 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $607,881.90. Following the transaction, the insider now owns 107,766 shares in the company, valued at approximately $4,536,948.60. The trade was a 11.82 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 5, 2025 | marketbeat.comInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells 25,000 Shares of StockUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CEO Emil D. Kakkis sold 25,000 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the completion of the transaction, the chief executive officer now owns 2,158,985 shares in the company, valued at $91,713,682.80. This represents a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 5, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells $3,091,571.40 in StockUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CEO Emil D. Kakkis sold 73,434 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the sale, the chief executive officer now directly owns 641,731 shares in the company, valued at approximately $27,016,875.10. The trade was a 10.27 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.March 5, 2025 | marketbeat.comTheodore Alan Huizenga Sells 967 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) StockMarch 5, 2025 | insidertrades.comInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Sells 2,990 Shares of StockMarch 4, 2025 | insidertrades.comFisher Asset Management LLC Purchases Shares of 265,189 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Fisher Asset Management LLC purchased a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 265,189 shares of the biopharMarch 4, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Sells $128,211.20 in StockUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the transaction, the executive vice president now owns 54,991 shares in the company, valued at $2,358,014.08. The trade was a 5.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.March 3, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and thirteFebruary 28, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd lifted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 39.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,695 shares of the biopharmaceutical company's stockFebruary 27, 2025 | marketbeat.comUltragenyx Pharmaceutical (RARE) Receives a Buy from Cantor FitzgeraldFebruary 26, 2025 | markets.businessinsider.comUltragenyx Pharmaceutical (NASDAQ:RARE) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday.February 26, 2025 | marketbeat.comState of New Jersey Common Pension Fund D Buys 11,745 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)State of New Jersey Common Pension Fund D increased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 33.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,514 sharFebruary 25, 2025 | marketbeat.comUltragenyx to Participate at Investor Conferences in MarchFebruary 24, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Icon (ICLR), Pediatrix Medical Group (MD) and Ultragenyx Pharmaceutical (RARE)February 23, 2025 | markets.businessinsider.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 19, 2025 | globenewswire.comUltragenyx Pharmaceutical (NASDAQ:RARE) Given New $136.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group lifted their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday.February 19, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Peregrine Capital Management LLCPeregrine Capital Management LLC increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 22.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 163,888 shares of the biopharmaceutical company's stock afterFebruary 19, 2025 | marketbeat.comUltragenyx price target raised to $136 from $121 at CanaccordFebruary 18, 2025 | markets.businessinsider.comBarclays Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)February 18, 2025 | markets.businessinsider.comAMERICAN SALARS ACQUIRES 18,083 HECTARE BRAZIL HARDROCK LCT PEGMATITE PROPERTY WITH RECENT SAMPLING UP TO 3.72% LI20 AND SIGNIFICANT RARE EARTHÂ ELEMENTÂ VALUESFebruary 18, 2025 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?February 15, 2025 | finance.yahoo.comHC Wainwright Reiterates "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)HC Wainwright reissued a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday.February 15, 2025 | marketbeat.comGoldman Sachs maintains buy on Ultragenyx, target at $78February 14, 2025 | msn.comBreaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their ViewsFebruary 14, 2025 | benzinga.comUltragenyx Pharmaceutical (RARE) Gets a Buy from RBC CapitalFebruary 14, 2025 | markets.businessinsider.comUltragenyx Pharmaceutical (NASDAQ:RARE) Announces Earnings ResultsUltragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%.February 14, 2025 | marketbeat.comUltragenyx reports Q4 EPS ($1.39), consensus ($1.27)February 14, 2025 | markets.businessinsider.comUltragenyx stock holds Buy rating, $140 target from TruistFebruary 14, 2025 | msn.comUltragenyx projects $640M-$670M in 2025 revenue growth driven by product launchesFebruary 14, 2025 | msn.com Remove Ads Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Media Mentions By Week RARE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼1.050.68▲Average Medical News Sentiment RARE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼107▲RARE Articles Average Week Remove Ads Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Moderna News Genmab A/S News Dr. Reddy's Laboratories News Viatris News Ascendis Pharma A/S News Vaxcyte News Qiagen News Roivant Sciences News Sarepta Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RARE Stock Free RARE Stock Alerts